Giving a common antioxidant called NAC to patients before a bone marrow transplant doesn't seem to make them any more or less likely to have serious complications like liver damage, rejection, or even death, compared to how patients did in the past without NAC.

36

Pro

0

Against

Evidence from Studies

Supporting (1)

36

Community contributions welcome

36

The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation

Case-Control Study

Human

The study gave patients NAC while they were getting a strong chemotherapy drug called busulphan, and found it didn’t change their chances of getting liver damage, rejection, or other complications—just like the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation

Score: 36

DOI: 10.1038/s41598-018-26033-z

Similar Assertions

When people get a special type of bone marrow transplant, they take a strong drug called busulfan to wipe out their old blood cells. Giving them a common antioxidant called NAC at a high dose doesn’t change how busulfan works in the body, so it won’t mess up the treatment’s ability to kill bad cells.

36

0

74%

When people get a special type of bone marrow transplant, giving them a common supplement called NAC twice a day might help protect their liver — in one study, far fewer patients on NAC had high levels of a liver damage marker called bilirubin compared to those who didn’t get it.

0

36

71%